Search research articles
Contact Us
Filters
Showing results (111-120 of 153) with videos related to
Page
of 16
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 3, 2008
Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells
Warren Fiskus, Yongchao Wang, Rajeshree Joshi, et al.
Blood
|
November 18, 2005
Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance
Joya Chandra, Jeannette Tracy, David Loegering, et al.
Nature Immunology
|
November 18, 2008
The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance
Alejandro Villagra, Fengdong Cheng, Hong-Wei Wang, et al.
Blood
|
September 3, 2010
Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists
Aditya Mandawat, Warren Fiskus, Kathleen M Buckley, et al.
Leukemia Research
|
June 12, 2022
Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine
Kunhwa Kim, Alexandre Bazinet, Sanam Loghavi, et al.
American Journal of Hematology
|
August 18, 2020
Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline RUNX1 mutations
Curtis Lachowiez, Sarah Bannon, Sanam Loghavi, et al.
The Journal of Clinical Investigation
|
November 3, 2010
BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy
Leandro C Cerchietti, Katerina Hatzi, Eloisi Caldas-Lopes, et al.
Breast Cancer Research and Treatment
|
June 7, 2014
A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer
Yifan Tu, Dawn L Hershman, Kapil Bhalla, et al.
The New England Journal of Medicine
|
June 16, 2006
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
Hagop Kantarjian, Francis Giles, Lydia Wunderle, et al.
Blood
|
August 24, 2007
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
Hagop M Kantarjian, Francis Giles, Norbert Gattermann, et al.
Page
of 16
Search research articles
Search
Showing results (111-120 of 153) with videos related to
Sort By:
Page
of 16
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 3, 2008
Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells
Warren Fiskus, Yongchao Wang, Rajeshree Joshi, et al.
Blood
|
November 18, 2005
Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance
Joya Chandra, Jeannette Tracy, David Loegering, et al.
Nature Immunology
|
November 18, 2008
The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance
Alejandro Villagra, Fengdong Cheng, Hong-Wei Wang, et al.
Blood
|
September 3, 2010
Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists
Aditya Mandawat, Warren Fiskus, Kathleen M Buckley, et al.
Leukemia Research
|
June 12, 2022
Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine
Kunhwa Kim, Alexandre Bazinet, Sanam Loghavi, et al.
American Journal of Hematology
|
August 18, 2020
Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline RUNX1 mutations
Curtis Lachowiez, Sarah Bannon, Sanam Loghavi, et al.
The Journal of Clinical Investigation
|
November 3, 2010
BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy
Leandro C Cerchietti, Katerina Hatzi, Eloisi Caldas-Lopes, et al.
Breast Cancer Research and Treatment
|
June 7, 2014
A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer
Yifan Tu, Dawn L Hershman, Kapil Bhalla, et al.
The New England Journal of Medicine
|
June 16, 2006
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
Hagop Kantarjian, Francis Giles, Lydia Wunderle, et al.
Blood
|
August 24, 2007
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
Hagop M Kantarjian, Francis Giles, Norbert Gattermann, et al.
Page
of 16